FinTrust Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

FinTrust Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$62K	Sell	1,339 -432	-24%	-$15.3K	0.01%	520
2024 Q2	$57.5K	Hold	1,771	–	–	0.01%	501
2024 Q1	$44.6K	Buy	1,771 +1,348	+319%	+$31.8K	0.01%	558
2023 Q4	$13.7K	Sell	423 -552	-57%	-$15.2K	﹤0.01%	774
2023 Q3	$26.6K	Buy	+975	New	+$28.2K	0.01%	609
2019 Q1	–	Sell	-253	Closed	-$3K	–	1264
2018 Q4	$3K	Buy	+253	New	+$3.34K	﹤0.01%	1035

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

FinTrust Capital Advisors's CORT Position: Q3 2024 in Review

FinTrust Capital Advisors reduced its Corcept Therapeutics (CORT) stake by 24% in Q3 2024, selling an estimated $15.3K and leaving 1,339 shares worth $62K. The position accounts for 0.01% of the portfolio, ranked #520.

FinTrust Capital Advisors first reported a position in CORT in Q4 2018 and has held it in 6 quarters since. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

FinTrust Capital Advisors held 1,339 shares of Corcept Therapeutics worth $62K as of Q3 2024.
FinTrust Capital Advisors sold 432 Corcept Therapeutics shares in Q3 2024, an estimated $15.3K.
Corcept Therapeutics made up 0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #520 holding.
FinTrust Capital Advisors first reported a position in Corcept Therapeutics in Q4 2018 and has held it in 6 quarters since.
321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.